zexitor 750mg tableta s prodlouženým uvolňováním - Resultados de la búsqueda

epirubicin hydrochloride injection solution

omega laboratories limited - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents

Canadá - inglés - Health Canada

pms-epirubicin solution

pharmascience inc - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents

Canadá - inglés - Health Canada

epirubicin hydrochloride injection solution

strides pharma canada inc - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents

Australia - inglés - Department of Health (Therapeutic Goods Administration)

xolair omalizumab (rch) 75mg powder for injection vial with diluent ampoule

novartis pharmaceuticals australia pty ltd - omalizumab, quantity: 75 mg - injection, solution - excipient ingredients: water for injections - allergic asthma,children 6 to < 12 years of age - in children aged 6 to <12 years, xolair is indicated as add-on therapy to improve asthma control in patients with severe allergic asthma who have documented exacerbations despite daily high dose inhaled corticosteroids, and who have immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,adults and adolescents 12 years of age and above -xolair is indicated for the management of adult and adolescent patients with moderate to severe allergic asthma, who are already being treated with inhaled steroids, and who have serum immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,chronic rhinosinusitis with nasal polyps (crswnp),xolair is indicated as add-on treatment in adult patients (18 years of age and above) for the treatment of severe crswnp with inadequate response to intranasal corticosteroids. recommended dosing is determined by serum immunoglobulin e levels and body weight corresponding to the recommended dose range in the product information (see section 4.2 dose and method of administration).,chronic spontaneous urticaria (csu),xolair is indicated for adults and adolescents (12 years of age and above) with chronic spontaneous urticaria who remain symptomatic despite h1 antihistamine treatment.